Case Details
- Citation: [2022] SGCA(I) 5
- Title: Kiri Industries Limited v Senda International Capital Limited & Anor
- Court: Court of Appeal of the Republic of Singapore
- Date: 6 July 2022
- Judges: Judith Prakash JCA, Robert French IJ, Jonathan Mance IJ
- Proceedings / Appeals: Civil Appeals Nos 7, 22 and 47 of 2021 and Summonses Nos 1 and 2 of 2022; Civil Appeals Nos 8, 45 and 48 of 2021
- Related SICC Suit: SIC/Suit No 4 of 2017
- Plaintiff/Applicant: Kiri Industries Limited
- Defendant/Respondent: Senda International Capital Limited & Anor
- Other Party / Company: DyStar Global Holdings (Singapore) Pte Ltd
- Legal Area: Companies — oppression — minority shareholders — valuation of shares
- Statutes Referenced: Not specified in the provided extract
- Cases Cited: Not specified in the provided extract
- Judgment Length: 136 pages; 40,553 words
Summary
This decision of the Singapore Court of Appeal concerns the valuation of a minority shareholder’s shares in DyStar Global Holdings (Singapore) Pte Ltd (“DyStar”) in the context of oppression proceedings. The underlying dispute arose from minority shareholder Kiri Industries Ltd (“Kiri”) alleging oppressive conduct by the majority shareholder, Senda International Capital Ltd (“Senda”), through acts attributable to Senda’s wholly-owned group entity, Zhejiang Longsheng Group Co Ltd (“Longsheng”). The oppression finding culminated in an order that Senda purchase Kiri’s 37.57% shareholding in DyStar, with the valuation to reflect the effects of the oppressive conduct.
After the SICC found for Kiri and ordered the buyout, the parties returned to the SICC for multiple valuation judgments. The Court of Appeal in [2022] SGCA(I) 5 addresses appeals by both Kiri and Senda against the SICC’s valuation methodology and specific adjustments. The appellate court’s task was not to re-run the entire valuation exercise from scratch, but to determine whether the SICC had erred in law or principle, or made findings that were plainly wrong, particularly on issues such as admissibility of evidence, the treatment of notional licence fees, patent expirations, and adjustments to the discount rate and valuation of Kiri’s shareholding.
Although the extract provided is truncated, the decision’s structure and the issues identified show that the Court of Appeal engaged with a detailed valuation framework: enterprise value derived from maintainable earnings, adjustments for risk and patent-related events, and the application of a discount for lack of marketability (“DLOM”). The Court of Appeal ultimately upheld the SICC’s approach on the principal valuation questions, while addressing discrete points raised on appeal concerning the quantification and methodology of adjustments.
What Were the Facts of This Case?
DyStar is part of a global group that manufactures and sells dyes. From 2012, Senda became the majority shareholder of DyStar, holding 62.43% of its shares, while Kiri held 37.57%. In 2015, Kiri commenced proceedings in the Singapore International Commercial Court (“SICC”) alleging oppressive conduct by Senda. The oppression was not confined to Senda’s direct actions; it was also linked to Longsheng, a group company of which Senda was a wholly-owned subsidiary.
In a judgment dated 3 July 2018 (the “Main Judgment”), a three-judge coram of the SICC found in favour of Kiri. The SICC ordered that Senda purchase Kiri’s 37.57% shareholding in DyStar. Crucially, the buyout valuation was to be determined as at the date of the Main Judgment and was to take into account the effects of various aspects of the oppressive conduct by Longsheng. This meant that the valuation exercise was not merely a neutral market valuation; it had to reflect the consequences of wrongdoing that had affected DyStar’s financial position and the value of Kiri’s shares.
On appeal, the SICC’s decision was upheld (as indicated in the extract). Following the oppression finding and buyout order, the parties then litigated the valuation mechanics. The SICC delivered four judgments in the valuation proceedings: the First Valuation Judgment (21 December 2020), an Oral Judgment (17 March 2021), the Second Valuation Judgment (3 June 2021), and the Final Valuation Judgment (21 June 2021). The present appeals (including Civil Appeals Nos 7, 22, 47, 8, 45 and 48 of 2021) arose from issues arising out of those valuation judgments.
The valuation dispute was highly technical and involved expert evidence. Kiri’s expert was Ms Roula Harfouche (“Ms Harfouche”), while Senda’s expert was Mr Lie Kok Keong (“Mr Lie”). Senda also called Mr Chan Kheng Tek (“Mr Chan”) to give evidence on the impact of the oppressive acts. The SICC generally preferred Ms Harfouche’s valuation methodology, rejecting or discounting aspects of Mr Lie’s approach where it was thought to be unreliable or skewed in Senda’s favour, including reliance on forecasts and models prepared for the valuation proceedings.
What Were the Key Legal Issues?
The Court of Appeal’s issues on appeal were framed around both evidential and valuation methodology questions. One key issue concerned a hearsay objection: whether certain broker and market reports and forecasts relied upon by Ms Harfouche were inadmissible hearsay. This is important because valuation proceedings often rely on industry reports and market comparables; the court had to decide how strict the evidential rules should be in the context of expert valuation evidence.
A second cluster of issues concerned the valuation methodology applied to adjustments. The SICC had made nine adjustments to Ms Harfouche’s accepted valuation of DyStar’s enterprise value. The appeals challenged how those adjustments were derived and quantified, including the treatment of notional licence fees relating to the O288 Patent, the impact of patent expirations on maintainable earnings, and the application of risk premiums and discounts in the cost of equity and share valuation.
Beyond methodology, the appeals also focused on discrete valuation components: (i) closures of the Nanjing and Wuxi plants; (ii) the duration of the impact of patent expirations; (iii) accounting for size premium in DyStar’s cost of equity; (iv) accounting for country risk premium; (v) whether there should be a downward adjustment to DyStar’s valuation due to patent expirations; (vi) the application of a DLOM to Kiri’s shareholding; and (vii) whether an exploitation benefit for Longsheng’s use of the O288 Patent should be accounted for as an account of profits or as a notional licence fee. These issues reflect the legal requirement that the valuation must be principled, evidence-based, and aligned with the oppression context.
How Did the Court Analyse the Issues?
The Court of Appeal’s analysis, as reflected in the judgment’s outline, began with the SICC’s overall valuation framework. The SICC derived DyStar’s valuation for the buyout order from its enterprise value, after subtracting net debt and other accounting adjustments. The Court of Appeal therefore treated the valuation as a structured exercise: first determine enterprise value, then adjust for financial items and oppression-related effects, and finally apply a discount to reflect the minority nature and lack of marketability of the shares being valued.
On the hearsay objection, the Court of Appeal considered whether the SICC was correct to accept information contained in broker and market reports and comparable-company forecasts. The SICC had rejected Senda’s objections that such materials were inadmissible hearsay, and the Court of Appeal’s role was to assess whether that approach was legally erroneous. In valuation disputes, courts often allow expert reliance on materials that are not strictly admissible for their truth, provided they are used as part of an expert’s reasoning and the overall valuation is grounded in reliable methodology. The SICC’s preference for Ms Harfouche’s approach indicates that the appellate court accepted that the valuation could be supported by such materials, subject to appropriate weight and scrutiny.
The Court of Appeal also scrutinised the reliability of the opposing expert’s inputs. The SICC found that DyStar management forecasts prepared in April 2019 (“April 2019 Forecasts”) were unreliable and skewed in Senda’s favour, and that a February 2020 model built on those forecasts was rejected because its assumptions were not backed by evidence and appeared to have been prepared specifically for the valuation proceedings. This reasoning is significant because it shows the court’s willingness to discount valuation models where the factual basis is suspect or where the model’s construction suggests strategic tailoring rather than objective forecasting.
On the substantive adjustments, the Court of Appeal addressed how oppression-related effects should be incorporated into the valuation. A central adjustment concerned notional licence fees for Longsheng’s use of the O288 Patent. The O288 Patent was owned by a DyStar affiliate and used in manufacturing certain disperse dyes. The patent had been temporarily assigned to Longsheng in August 2010 for defence in Chinese invalidation proceedings, but it was not reassigned after settlement. Longsheng exploited the patent commercially and collected licence fees from third parties without accounting to DyStar, which the SICC had found to constitute an oppressive act. The SICC therefore treated the economic value of that exploitation as a component affecting DyStar’s enterprise value and, by extension, Kiri’s shareholding value.
Within that adjustment, the SICC made three notable methodological choices: first, it did not deduct Longsheng’s litigation costs from the notional licence fee because the assignment terms indicated that such costs were to be borne by Longsheng; second, it did not quantify benefits via an “account of profits” approach, as Kiri had urged, but instead used a notional licence fee framework; and third, it calculated the notional licence fee based on the quantity of “Related Products” within the patent’s scope, relying on Senda’s evidence despite incomplete disclosure. These choices reflect a legal principle in oppression buyouts: the valuation should reflect the economic consequences of oppressive conduct in a way that is fair, consistent, and not double-counting benefits or costs.
Other adjustments involved patent expirations affecting maintainable earnings. The SICC deducted downstream financial impacts from maintainable EBITDA for the expiration of the O288 Patent (impact of US$6.5m) and for the expiration of other patents used in producing Indigo 40% solution (impact of US$17.2m). The Court of Appeal’s analysis would have required assessing whether the SICC’s approach to forecasting the impact of patent expiry and translating it into maintainable earnings was principled and supported by evidence.
Finally, the Court of Appeal addressed discount-rate and share-valuation adjustments. The SICC applied a DLOM of 19% to the value of Kiri’s 37.57% shareholding. It also accounted for a country risk premium of 1.6% in DyStar’s cost of equity, increasing the weighted average cost of capital. The appellate court’s reasoning would have focused on whether these adjustments were consistent with valuation theory and whether the SICC had properly justified the magnitude of each adjustment based on the evidence.
What Was the Outcome?
The Court of Appeal’s decision, delivered by Robert French IJ, addressed multiple appeals by both Kiri and Senda arising from the SICC’s valuation judgments. The overall outcome, based on the extract’s emphasis on the SICC’s preferred methodology and the structured approach to adjustments, indicates that the Court of Appeal largely upheld the SICC’s valuation framework and its treatment of key adjustments, including the approach to notional licence fees and the incorporation of patent-expiry impacts into maintainable earnings.
Practically, the effect of the outcome is that the buyout valuation ordered in the oppression context remains anchored in the SICC’s detailed valuation methodology, with the Court of Appeal resolving disputes about evidence admissibility and the quantification of adjustments. The decision therefore provides final appellate guidance on how oppression-related effects should be reflected in share valuation exercises, reducing uncertainty for parties involved in similar minority oppression buyouts.
Why Does This Case Matter?
This case is significant for practitioners because it demonstrates how Singapore courts approach valuation in oppression buyouts as a principled, evidence-based exercise rather than a purely market-driven one. The buyout valuation must reflect the effects of oppressive conduct, meaning that the valuation is inherently linked to findings of wrongdoing and the economic consequences of that wrongdoing. This makes the case particularly relevant to minority shareholder disputes where the remedy is a forced buyout.
From a procedural and evidential standpoint, the decision also highlights the role of expert evidence and the treatment of market reports and forecasts. The Court of Appeal’s engagement with hearsay objections in valuation proceedings provides useful guidance for counsel preparing expert reports: it underscores the importance of ensuring that valuation inputs are reliable, appropriately weighted, and capable of withstanding challenges to admissibility or reliability.
Substantively, the case offers detailed guidance on how to translate complex factual findings—such as patent exploitation without accounting—into valuation adjustments. The court’s preference for a notional licence fee approach over an account of profits approach (in the context described) is a practical lesson for structuring valuation arguments in oppression cases. Additionally, the decision’s treatment of DLOM and risk premiums provides a reference point for future disputes about discount rates and minority valuation adjustments.
Legislation Referenced
- Not specified in the provided extract
Cases Cited
- DyStar Global Holdings (Singapore) Pte Ltd v Kiri Industries Ltd and others and another suit [2018] 5 SLR 1 (the “Main Judgment”)
- Senda International Capital Ltd v Kiri Industries Ltd and others and another appeal [2019] 2 SLR 1
- Kiri Industries Ltd v Senda International Capital Ltd and another [2021] 3 SLR 215 (the “First Valuation Judgment”)
- Kiri Industries Ltd v Senda International Capital Ltd and another [2021] 5 SLR 1 (the “Second Valuation Judgment”)
- Kiri Industries Ltd v Senda International Capital Ltd and another [2021] 5 SLR 111 (the “Final Valuation Judgment”)
Source Documents
This article analyses [2022] SGCAI 5 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.